UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Commission File Number 001-37381
MEDIGUS LTD.
(Translation of registrant’s name into English)
10 HaNechoshet Street Tel-Aviv, 6971072, Israel
(Address of principal
executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
EXPLANATORY NOTE
On November 13, 2023, Medigus
Ltd. issued a press release titled: “Medigus: Metagramm to Develop Bubbl, its Most Advanced AI-Powered Writing and Grammar Tool.”
A copy of this press release is furnished herewith as Exhibit 99.1
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
MEDIGUS LTD. |
| |
|
|
| Date: November 13, 2023 |
By: |
/s/ Tali Dinar |
| |
|
Tali Dinar |
| |
|
Chief Financial Officer |
3
Exhibit 99.1
Medigus:
Metagramm to Develop Bubbl, its Most Advanced AI-Powered Writing and Grammar Tool
Bubbl’s technology allows for innovative
document re-writing and sets a new standard in the domain of writing aids
Tel Aviv, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies,
and electric vehicle and charging solutions, announced today that its subsidiary (19.99% owned), Metagramm Software Ltd. (“Metagramm”),
is developing Bubbl, a state-of-the-art writing tool utilizing Machine Learning, Natural Language Processing (NLP), Artificial Intelligence
(AI) and Deep Learning technologies.
According to Verified Market Research, the Global
Writing Enhancement Software market will reach $887.9 million by 2030 with an impressive 11% CAGR from 2023-2030.
The Company anticipates Bubbl to significantly
impact the market for writing tools, providing users with an unmatched writing experience.
In an effort to offer an unrivaled user experience,
Bubbl has been crafted with a minimalistic and clean design, presenting a non-invasive writing tool. It allows users to operate in different
modes, including an interactive re-write floating window mode, interactive inline mode and grammar-only mode.
Bubbl represents a revolution in the field of
writing tools, integrating classic semantic analysis, pre-training, and reinforcement learning of Specialized Language Models (SLMs) and
Large Language Models (LLMs). This advanced technology allows for innovative document re-writing and sets a new standard in the domain
of writing aids.
A notable feature of Bubbl is “Click Writing”,
a unique, user-friendly tool that enables users to enhance and re-write their text effortlessly. A simple interaction with Bubbl allows
users to access automatically revised text suggestions instantaneously.
Moreover, Bubbl is designed to cater to a variety
of writing needs with different profiles and features, including Business, Medical, Academic and Blogging. Each profile incorporates tailored
assistive tools that greatly facilitate the writing process for each specific profile.
With Metagramm’s new development, Bubbl,
Medigus continues its legacy of pioneering advanced technologies that may disrupt and redefine their respective fields.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle
markets. Medigus’ affiliations in the medical solutions arena include ownership in Polyrizon Ltd. The Company’s affiliates in digital
commerce include Gix Internet Ltd., Jeffs’ Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics
Ltd. and Revoltz Ltd., by way of Fuel Doctor Holdings, Inc. and ParaZero Technologies Ltd. are also part of the Company’s portfolio
of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking
statements. Because such statements deal with future events and are based on Medigus’ current expectations, they are subject to
various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied
by the statements in this press release. For example, Medigus uses forward looking statements when describing Bubbl’s potential in
the global writing enhancement software market.
The forward-looking statements contained or implied
in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise
required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been
provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus
is not responsible for the contents of third-party websites.
Company Contact:
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Investor Relations Contact:
Michal Efraty
Investor Relations, Israel
+972-(0)52-3044404
michal@efraty.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024
